PHARMACEUTICAL 2013

XOMA Royalty Corp
Rank 152 of 218



PHARMACEUTICAL 2013

XOMA Royalty Corp
Rank 152 of 218

The relative strengths and weaknesses of XOMA Royalty Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of XOMA Royalty Corp compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 3.0% points.The greatest weakness of XOMA Royalty Corp is the variable Stockholders Equity, reducing the Economic Capital Ratio by 58% points.

The company's Economic Capital Ratio, given in the ranking table, is 140%, being 80% points below the market average of 220%.

Input Variable	Value in 1000 USD
Assets, Current	95,837
Cost of Goods Sold	143
Intangible Assets	0
Liabilities, Current	23,657
Liabilities, Non-Current	39,060
Other Assets	1,696
Other Compr. Net Income	8.0
Other Expenses	9,387
Other Liabilities	21,316
Other Net Income	-10,128
Other Revenues	33,782
Property and Equipment	8,143
Research and Development	68,231
Selling, General and Administrative Expense	16,782

Output Variable	Value in 1000 USD
Assets	105,676
Liabilities	84,033
Expenses	94,543
Revenues	33,782
Stockholders Equity	21,643
Net Income	-70,889
Comprehensive Net Income	-70,885
BaseVar	164,085
ECR before LimitedLiability	-25%
Economic Capital Ratio	140%